APP and APLP2 Kunitz Domains Are Potent Endogenous Inhibitors of TMPRSS2 and Respiratory Virus Infection
Jan Lawrenz, Shreyans Chatterjee, Armando Rodríguez Alfonso…·Jan Münch
Author
Universität UlmORCID 0000-0002-4763-1104Unclaimed ORCID profile · follow to get notified of new preprints
4 papers
Recent·Most cited
Jan Lawrenz, Shreyans Chatterjee, Armando Rodríguez Alfonso…·Jan Münch
Rinu Sivarajan, Paul C. Kirchgatterer, Jan Lawrenz…·Konstantin M. J. Sparrer
The paper demonstrates that tonic interferons are critical for early antiviral defense in human lung organoid-derived air-liquid interface cultures against HRV16.
Annalena Branz, Irina Shalashova, Anastasia M. Funk…·Muriel Lizé
This paper identifies PMVEC alterations in IPF using single-cell RNA sequencing and spatial transcriptomics, develops endothelial injury models, and validates functional assays for drug discovery.
Jan Lawrenz, Lukas Wettstein, Armando Rodríguez…·Jan Münch
This paper identifies Trypstatin, a Kunitz-type protease inhibitor that inhibits TMPRSS2 and related proteases, showing broad-spectrum antiviral activity against SARS-CoV-2, influenza, and other respiratory viruses.